During cancer treatment, Chemotherapy-Induced Nausea and Vomiting (CINV) remains one of the most significant factors affecting patients’ treatment experience. Although advances in oncology therapies have improved overall treatment outcomes in recent years, adverse effects such as nausea and vomiting still severely impact patients’ eating, sleep, and daily activities, and may even lead some patients to discontinue chemotherapy.
Currently, neurokinin-1 (NK-1) receptor antagonists have become core antiemetic agents for chemotherapy regimens with moderate to high emetogenic risk. Among them, Aprepitant plays a key role in controlling delayed nausea and vomiting by blocking the binding of substance P to NK-1 receptors, making it an important component of first-line antiemetic therapy.
However, with broader clinical application, the issues of “low solubility and poor absorption” associated with aprepitant have become increasingly apparent. In recent years, research on novel formulations and advanced drug delivery systems for aprepitant has rapidly expanded, driving CINV treatment into an era of more efficient drug absorption.
Why Does Aprepitant Face Absorption Challenges?
From a pharmaceutical perspective, aprepitant is classified as a typical BCS Class IV drug, meaning it exhibits both low solubility and low permeability. Studies have shown that its aqueous solubility is only around 3–7 μg/mL across a pH range of 2–10, which significantly limits absorption after oral administration.
Traditional formulations also present several limitations:
|
Limitations of Traditional Aprepitant Formulations |
Clinical Impact |
|
Low water solubility |
Limited bioavailability |
|
Strong food effects |
Significant fluctuations in efficacy |
|
Hepatic first-pass metabolism |
Reduced actual drug absorption |
|
Difficult oral administration in severe vomiting patients |
Reduced treatment convenience |
|
Intravenous formulations require infusion |
Limited long-term adherence |
For patients already experiencing severe nausea and vomiting, oral administration itself can become challenging. Therefore, improving drug absorption efficiency and optimizing administration methods have become major directions in aprepitant development.
Why Is Drug Delivery Becoming Increasingly Important in CINV Treatment?
In the past, antiemetic drug development focused mainly on whether the drug itself was effective. Today, however, the industry is paying increasing attention to:
- Whether the drug can be absorbed consistently
- Whether rapid onset can be achieved
- Whether drug action duration can be extended
- Whether long-term patient experience can be improved
As a result, the development of new aprepitant formulations is shifting from “simply controlling vomiting” toward “efficient drug delivery.”
Current global research hotspots include nanotechnology-based formulations, solid dispersions, self-microemulsifying drug delivery systems (SMEDDS), and long-acting sustained-release technologies. The shared objective of these approaches is to improve the solubility and bioavailability of aprepitant.
Nanotechnology Is Enhancing Aprepitant Absorption
Nanotechnology-based formulations are currently among the most active research areas for aprepitant. Their core principle involves reducing drug particles to the nanoscale, thereby dramatically increasing surface area and improving dissolution and absorption efficiency.
Compared with conventional formulations, nanotechnology offers several advantages:
- Faster drug dissolution
- Enhanced gastrointestinal absorption
- Improved bioavailability
- Reduced plasma concentration fluctuations
Studies have shown that nano-formulated aprepitant can enter systemic circulation more rapidly, thereby improving antiemetic efficacy. In addition, nanoparticle delivery systems may help reduce the impact of food on drug absorption.
At present, technologies such as nanocrystals, polymeric nanoparticles, and lipid-based nanocarriers are all under active development.
Self-Microemulsifying Systems Are Emerging as a Key Research Direction
Due to the highly lipophilic nature of aprepitant, self-microemulsifying drug delivery systems (SMEDDS) have also attracted considerable attention in recent years.
These systems can rapidly form tiny emulsion droplets in the gastrointestinal tract, significantly improving drug dispersion and dissolution efficiency. Compared with conventional oral formulations, SMEDDS can further enhance absorption stability and reduce interpatient variability.
Dengyue believes that self-microemulsifying technology may not only benefit aprepitant, but could also be widely applied to many other poorly soluble anticancer drugs in the future.
Sustained-Release and Long-Acting Technologies Are Improving Patient Experience
As chronic disease management concepts continue to evolve, antiemetic therapy is increasingly focusing on long-term treatment experience.
Although traditional aprepitant formulations are effective, they may still present issues such as large plasma concentration fluctuations and relatively frequent dosing schedules. Therefore, sustained-release and long-acting drug delivery systems are becoming new research priorities.
By controlling drug release rates, novel sustained-release systems can prolong drug action while maintaining more stable plasma concentrations. This may not only improve antiemetic efficacy, but also reduce the overall treatment burden for patients.
For patients requiring multiple cycles of chemotherapy, long-acting antiemetic strategies are becoming increasingly valuable.
New Administration Routes Are Expanding Clinical Applications
Beyond traditional oral and intravenous administration, researchers are also exploring innovative delivery routes such as intranasal delivery, transdermal administration, and buccal mucosal delivery.
The primary goal of these novel delivery approaches is to bypass gastrointestinal limitations and improve drug absorption efficiency.
Particularly for patients already experiencing severe vomiting, non-oral administration methods may provide greater clinical value. In the future, multi-route drug delivery strategies may become an important direction for precision management of CINV.
CINV Treatment Is Entering the Era of Efficient Drug Delivery
As supportive oncology care continues to evolve, the industry has gradually recognized that antiemetic therapy not only affects patient comfort, but also directly influences the overall effectiveness of anticancer treatment.
As a result, future competition in CINV treatment will depend not only on the drug itself, but also on factors such as:
- Drug delivery efficiency
- Long-acting capabilities
- Speed of onset
- Convenience of administration
- Patient adherence
The development of new aprepitant formulations reflects this broader trend. From nanotechnology to intelligent drug delivery systems, modern pharmaceutical technologies are redefining supportive cancer care.
Conclusion
As an important NK-1 receptor antagonist for CINV treatment, aprepitant has already demonstrated significant clinical value in controlling delayed nausea and vomiting. However, its low solubility and poor absorption have long limited the full realization of its therapeutic potential.
In recent years, with the rapid advancement of nanotechnology, self-microemulsifying systems, and sustained-release drug delivery platforms, aprepitant is gradually transitioning from a “poorly soluble drug” to a new generation of “high-efficiency absorption therapies.”
Looking ahead, as more innovative formulation technologies continue to mature, CINV treatment is expected to move further toward precision, long-acting, and individualized therapy, ultimately providing cancer patients with more stable, convenient, and effective supportive care experiences.